
    
      Subjects enrolled in the 401GSDIA01 study will be monitored for 52 weeks following DTX401
      administration. Subjects in Cohorts 1, 2, and 3 will receive reactive oral steroid treatment
      for possible vector-induced hepatitis following treatment with DTX401. Subjects in Cohort 4
      will receive prophylactic oral steroid treatment to prevent possible vector-induced
      hepatitis. After completion of the Week 52 visit or early withdrawal, subjects will be
      offered enrollment into a 4-year extension study.
    
  